title: (18)F-FDG-PET and PET/CT for Evaluating Primary Bone Tumors.
abstract: Imaging is critical for the proper evaluation of patients with primary tumors of bone. There is a growing role for (18)F-fluorodeoxyglucose PET and PET/computed tomography (CT) in the grading, staging, prognostication, evaluation of therapeutic response, and detection of recurrent disease in bone. These modalities can also be used to help differentiate benign from malignant disorders of bone.
authors.affiliation: Division of Nuclear Medicine, Department of Radiology, Stanford Hospital and Clinics, 300 Pasteur Drive, Room H0101, Stanford, CA 94305-8521, USA. Electronic address: erik.mittra@stanford.edu.
authors.forename: Erik
authors.initials: E
authors.lastname: Mittra
authors.affiliation: Division of Nuclear Medicine, Department of Radiology, Stanford Hospital and Clinics, 300 Pasteur Drive, Room H0101, Stanford, CA 94305-8521, USA.
authors.forename: Andrei
authors.initials: A
authors.lastname: Iagaru
keywords: Benign; Fluorodeoxyglucose; Malignant; Multiple myeloma; Positron emission tomography; Sarcoma